This should get Trius past the 5.37 resistance where the 200 day moving average currently sits. Next resistance lines are at 5.60 and 5.95 then 6.45. With about 6-7 weeks left, we have plenty of time for this stock to run to data.
JAMA has an impact factor of ~30 and is one of the most highly respected peer reviewed journals out there. It's not very easy to get published in JAMA. My faith in management has grown as a result.
Beavertailsucker, you better put down that pot and cover his short position before it's too late.
"In an accompanying editorial in the JAMA issue, Drs. Shira Doron and Helen Boucher state, "Much can be learned from the current study about the appropriate use of antibiotics for the treatment of these common infections, and the design of future trials for treatment of ABSSSI." They also highlight that "Tedizolid is a new oral antibiotic that appears efficacious using a short course of therapy and may have a better safety profile than linezolid."
In December 2012, Trius announced that it completed enrollment of its second ABSSSI trial, ESTABLISH 2. This second pivotal Phase 3 trial was designed to evaluate the efficacy and safety of tedizolid and linezolid when initially administered as an intravenous (IV) infusion with the option to switch to oral therapy. Trius expects to report top-line results from the ESTABLISH 2 study around the end of the first quarter of this year"